Exelixis, Inc. (NASDAQ:EXEL) has earned a consensus recommendation of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $32.57.

Several brokerages recently commented on EXEL. BidaskClub lowered Exelixis from a “buy” rating to a “hold” rating in a report on Friday. Oppenheimer reaffirmed a “hold” rating on shares of Exelixis in a report on Wednesday, January 17th. Cann reaffirmed a “hold” rating on shares of Exelixis in a report on Thursday, January 4th. Zacks Investment Research raised Exelixis from a “hold” rating to a “strong-buy” rating and set a $35.00 price objective for the company in a report on Tuesday, January 2nd. Finally, SunTrust Banks reiterated a “buy” rating and set a $38.00 target price on shares of Exelixis in a research report on Thursday, December 21st.

In related news, Director Alan M. Garber sold 15,000 shares of Exelixis stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now directly owns 64,829 shares in the company, valued at $1,964,318.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 5.10% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EXEL. Mark Sheptoff Financial Planning LLC purchased a new position in Exelixis during the third quarter valued at $120,000. Fisher Asset Management LLC purchased a new position in shares of Exelixis in the third quarter valued at about $213,000. Caxton Associates LP purchased a new position in shares of Exelixis in the second quarter valued at about $227,000. Raymond James Financial Services Advisors Inc. purchased a new position in shares of Exelixis in the third quarter valued at about $236,000. Finally, CIBC Asset Management Inc purchased a new position in shares of Exelixis in the third quarter valued at about $238,000. Institutional investors own 80.92% of the company’s stock.

Shares of Exelixis (EXEL) opened at $29.44 on Tuesday. Exelixis has a fifty-two week low of $16.72 and a fifty-two week high of $32.50. The company has a market capitalization of $8,710.00, a price-to-earnings ratio of 60.08, a P/E/G ratio of 0.84 and a beta of 1.88.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. During the same quarter in the previous year, the company posted ($0.04) earnings per share. Exelixis’s revenue was up 145.2% compared to the same quarter last year. equities analysts predict that Exelixis will post 0.49 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://theolympiareport.com/2018/01/23/exelixis-inc-exel-receives-average-rating-of-buy-from-analysts.html.

About Exelixis

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.